PEG化医薬品の世界市場 (～2035年)：分子 (高分子医薬品・低分子医薬品・脂質ナノ粒子&リポソーム)・用途・流通経路・地域別

PEG化医薬品の市場規模は、予測期間中にCAGR 5.17%で大幅な成長を示すと予測されています。

PEG化とは、共有結合および非共有結合のグリコールポリマー鎖を、ペプチド、タンパク質、抗体フラグメント、酵素、オリゴヌクレオチドなどの生理活性分子に結合させることです。これは、臨床環境において薬剤の治療効果を向上させる安全な戦略です。治療現場で使用されるFDA認可のPEG化医薬品はさまざまなものがあります。

慢性疾患の有病率の増加、生物製剤の進歩、新たに承認されたPEG化医薬品が、世界のペグインターフェースの市場を牽引しています。一方で、高い製造コスト、規制上の障壁、そして潜在的な副作用が市場成長の制限要因となっています。しかし、拡大する市場、新たな薬物送達技術、個別化医療の進展により、将来的な市場成長の可能性が期待されています。

地域別分析

北米は2024年に最大の市場シェアを占め、2035年には89億6,941万米ドルに達すると予想されています。一方で、アジア太平洋は予測期間中にCAGR 7.03％で最大の成長を示すと予測されています。

北米市場では米国とカナダが優位を示しています。癌などの慢性疾患の増加が市場拡大の原動力となっています。

欧州各国政府による慢性疾患の抑制に向けた支援と投資が、欧州地域の拡大を後押ししています。

当レポートでは、世界のPEG化医薬品の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

• 促進要因
  • 慢性疾患の発生率の増加
  • 生物学の進歩
  • 最近承認されたPEG化医薬品
• 抑制要因
  • 高い生産コスト
  • 規制上の障壁
  • 潜在的な副作用
• 機会
  • 新興市場
  • 革新的な薬剤送達システム
  • 個別化医療

第5章 市場要因分析

• ポーターのファイブフォース分析
• COVID-19が世界のPEG化医薬品市場に与える影響
• 抗PEG抗体の定性分析とPEG化医薬品への影響

第6章 世界のPEG化医薬品市場：分子別

• 概要
• 高分子医薬品
  • タンパク質とペプチド
  • 酵素
  • アプタマー
• 低分子医薬品
• 脂質ナノ粒子 (LNP) とリポソーム

第7章 世界のPEG化医薬品市場：用途別

• 概要
• 腫瘍
• 神経
• 自己免疫疾患
• 血液
• その他

第8章 世界のPEG化医薬品市場：流通チャネル別

• 概要
• 病院薬局
• オンライン薬局
• 小売薬局

第9章 世界のPEG化医薬品市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他
• その他の地域
  • 中東・アフリカ
  • 南米

第10章 競合情勢

• 市場シェア分析
• 競合ダッシュボード
• 公開企業の株式概要
• 比較分析：主要企業の財務動向
• 主な展開と成長戦略

第11章 企業プロファイル

• AMGEN INC.
• PFIZER INC.
• BIOGEN
• BAYER AG
• TAKEDA PHARMACEUTICAL COMPANY LIMITED
• NOVO NORDISK A/S
• SANDOZ GROUP AG
• ASTRAZENECA
• COHERUS BIOSCIENCES, INC.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON INC.
• ALNYLAM PHARMACEUTICALS, INC.
• LES LABORATOIRES SERVIER

第12章 データの引用

LIST OF TABLES

• TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
• TABLE 2 RECENTLY APPROVED PEGYLATED DRUGS IN U.S., AUSTRALIA, JAPAN, AND CANADA
• TABLE 3 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 4 GLOBAL PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY REGION, 2019-2035 (USD MILLION)
• TABLE 5 GLOBAL PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 6 GLOBAL PEGYLATED DRUGS MARKET, FOR PROTEIN AND PEPTIDE, BY REGION, 2019-2035 (USD MILLION)
• TABLE 7 GLOBAL PEGYLATED DRUGS MARKET, FOR ENZYME, BY REGION, 2019-2035 (USD MILLION)
• TABLE 8 GLOBAL PEGYLATED DRUGS MARKET, FOR APTAMER, BY REGION, 2019-2035 (USD MILLION)
• TABLE 9 GLOBAL PEGYLATED DRUGS MARKET, FOR SMALL MOLECULAR DRUGS, BY REGION, 2019-2035 (USD MILLION)
• TABLE 10 GLOBAL PEGYLATED DRUGS MARKET, FOR LIPID NANOPARTICLES (LNP) AND LIPOSOMES, BY REGION, 2019-2035 (USD MILLION)
• TABLE 11 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 12 GLOBAL PEGYLATED DRUGS MARKET, FOR ONCOLOGY, BY REGION, 2019-2035 (USD MILLION)
• TABLE 13 GLOBAL PEGYLATED DRUGS MARKET, FOR NEUROLOGY, BY REGION, 2019-2035 (USD MILLION)
• TABLE 14 GLOBAL PEGYLATED DRUGS MARKET, FOR AUTOIMMUNE DISEASES, BY REGION, 2019-2035 (USD MILLION)
• TABLE 15 GLOBAL PEGYLATED DRUGS MARKET, FOR HAEMATOLOGY, BY REGION, 2019-2035 (USD MILLION)
• TABLE 16 GLOBAL PEGYLATED DRUGS MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD MILLION)
• TABLE 17 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 18 GLOBAL PEGYLATED DRUGS MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2019-2035 (USD MILLION)
• TABLE 19 GLOBAL PEGYLATED DRUGS MARKET, FOR ONLINE PHARMACY, BY REGION, 2019-2035 (USD MILLION)
• TABLE 20 GLOBAL PEGYLATED DRUGS MARKET, FOR RETAIL PHARMACY, BY REGION, 2019-2035 (USD MILLION)
• TABLE 21 GLOBAL PEGYLATED DRUGS MARKET, BY REGION, 2019-2035 (USD MILLION)
• TABLE 22 NORTH AMERICA PEGYLATED DRUGS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
• TABLE 23 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 24 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 25 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 26 NORTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 27 US: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 28 US: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 29 US: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 30 US: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 31 CANADA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 32 CANADA: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 33 CANADA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 34 CANADA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 35 EUROPE PEGYLATED DRUGS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
• TABLE 36 EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 37 EUROPE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 38 EUROPE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 39 EUROPE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 40 GERMANY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 41 GERMANY: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 42 GERMANY: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 43 GERMANY: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 44 FRANCE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 45 FRANCE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 46 FRANCE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 47 FRANCE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 48 UK: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 49 UK: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 50 UK: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 51 UK: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 52 ITALY: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 53 ITALY: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 54 ITALY: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 55 ITALY: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 56 SPAIN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 57 SPAIN: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 58 SPAIN: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 59 SPAIN: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 60 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 61 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 62 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 63 REST OF EUROPE: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 64 ASIA-PACIFIC PEGYLATED DRUGS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
• TABLE 65 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 66 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 67 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 68 ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 69 CHINA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 70 CHINA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 71 CHINA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 72 CHINA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 73 INDIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 74 INDIA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 75 INDIA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 76 INDIA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 77 JAPAN: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 78 JAPAN: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 79 JAPAN: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 80 JAPAN: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 81 AUSTRALIA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 82 AUSTRALIA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 83 AUSTRALIA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 84 AUSTRALIA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 85 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 86 SOUTH KOREA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 87 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 88 SOUTH KOREA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 89 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 90 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 91 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 92 REST OF ASIA-PACIFIC: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 93 REST OF THE WORLD PEGYLATED DRUGS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
• TABLE 94 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 95 REST OF THE WORLD: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 96 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 97 REST OF THE WORLD: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 98 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 99 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 100 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 101 MIDDLE EAST & AFRICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 102 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
• TABLE 103 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 104 SOUTH AMERICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 105 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 106 SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 107 BRAZIL: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 108 BRAZIL: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 109 BRAZIL: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 110 BRAZIL: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 111 MEXICO: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 112 MEXICO: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 113 MEXICO: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 114 MEXICO: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 115 ARGENTINA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 116 ARGENTINA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 117 ARGENTINA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 118 ARGENTINA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 119 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY MOLECULE, 2019-2035 (USD MILLION)
• TABLE 120 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, FOR MACROMOLECULAR DRUGS, BY TYPE, 2019-2035 (USD MILLION)
• TABLE 121 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 122 REST OF SOUTH AMERICA: PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 123 PRODUCT APPROVAL
• TABLE 124 PRODUCT EXPANSION
• TABLE 125 APPROVAL DENIED
• TABLE 126 PRODUCT DISCONTINUATION
• TABLE 127 AGREEMENT/ACQUISITION
• TABLE 128 CLINICAL TRIAL FINDINGS
• TABLE 129 AMGEN INC.: PRODUCTS OFFERED
• TABLE 130 AMGEN INC.: KEY DEVELOPMENTS
• TABLE 131 PFIZER INC.: PRODUCTS OFFERED
• TABLE 132 PFIZER INC.: KEY DEVELOPMENTS
• TABLE 133 BIOGEN: PRODUCTS OFFERED
• TABLE 134 BIOGEN: KEY DEVELOPMENTS
• TABLE 135 BAYER AG: PRODUCTS OFFERED
• TABLE 136 BAYER AG: KEY DEVELOPMENTS
• TABLE 137 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED
• TABLE 138 TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY DEVELOPMENTS
• TABLE 139 NOVO NORDISK A/S: PRODUCTS OFFERED
• TABLE 140 NOVO NORDISK A/S: KEY DEVELOPMENTS
• TABLE 141 SANDOZ GROUP AG: PRODUCTS OFFERED
• TABLE 142 SANDOZ GROUP AG: KEY DEVELOPMENTS
• TABLE 143 ASTRAZENECA: PRODUCTS OFFERED
• TABLE 144 ASTRAZENECA: KEY DEVELOPMENTS
• TABLE 145 COHERUS BIOSCIENCES, INC.: PRODUCTS OFFERED
• TABLE 146 COHERUS BIOSCIENCES, INC.: KEY DEVELOPMENTS
• TABLE 147 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
• TABLE 148 JOHNSON & JOHNSON INC.: PRODUCTS OFFERED
• TABLE 149 ALNYLAM PHARMACEUTICALS, INC: PRODUCTS OFFERED
• TABLE 150 ALNYLAM PHARMACEUTICALS, INC: KEY DEVELOPMENTS
• TABLE 151 LES LABORATOIRES SERVIER: PRODUCTS OFFERED

LIST OF FIGURES

• FIGURE 1 GLOBAL PEGYLATED DRUGS MARKET: STRUCTURE
• FIGURE 2 GLOBAL PEGYLATED DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035)
• FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2035)
• FIGURE 4 RESTRAINT IMPACT ANALYSIS (2024-2035)
• FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PEGYLATED DRUGS MARKET
• FIGURE 6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE, 2024 & 2035 (USD MILLION)
• FIGURE 7 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY MOLECULE, 2024
• FIGURE 8 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION)
• FIGURE 9 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY APPLICATION, 2024
• FIGURE 10 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD MILLION)
• FIGURE 11 GLOBAL PEGYLATED DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024
• FIGURE 12 GLOBAL PEGYLATED DRUGS MARKET SHARE, BY REGION, 2024 & 2035 (USD MILLION)
• FIGURE 13 GLOBAL PEGYLATED DRUGS MARKET SHARE, BY REGION, 2024 (%)
• FIGURE 14 NORTH AMERICA PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
• FIGURE 15 NORTH AMERICA PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 16 EUROPE PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
• FIGURE 17 EUROPE PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 18 ASIA-PACIFIC PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
• FIGURE 19 ASIA-PACIFIC PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 20 REST OF THE WORLD PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
• FIGURE 21 REST OF THE WORLD PEGYLATED DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 22 GLOBAL PEGYLATED DRUGS MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024
• FIGURE 23 COMPETITOR DASHBOARD: GLOBAL PEGYLATED DRUGS MARKET
• FIGURE 24 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 25 AMGEN INC.: SWOT ANALYSIS
• FIGURE 26 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 27 PFIZER INC.: SWOT ANALYSIS
• FIGURE 28 BIOGEN: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 29 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 30 BAYER AG: SWOT ANALYSIS
• FIGURE 31 TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 32 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 33 NOVO NORDISK A/S: SWOT ANALYSIS
• FIGURE 34 SANDOZ GROUP AG: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 35 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 36 COHERUS BIOSCIENCES, INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 37 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 38 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
• FIGURE 39 JOHNSON & JOHNSON INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 40 JOHNSON & JOHNSON INC.: SWOT ANALYSIS
• FIGURE 41 ALNYLAM PHARMACEUTICALS, INC: FINANCIAL OVERVIEW SNAPSHOT

Global PEGylated Drugs Market Research Report Information by Molecule (Macromolecular Drugs, Small Molecular Drugs and Lipid Nanoparticles (LNP) and Liposomes), by Application (Oncology, Neurology, Autoimmune Diseases, Haematology and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) Forecast till 2035

Market Overview

The PEGylated Drugs Market is expected to grow at a substantial CAGR of 5.17% during the review period. Pegylation is the process of binding covalent and non-covalent glycol polymer chains to bioactive molecules such as peptides, proteins, antibody fragments, enzymes, and oligonucleotides. It is a safe strategy for improving the therapeutic efficacy of drugs in a clinical environment. There are various FDA-approved pegylated medicines used in therapeutic settings.

The growing prevalence of chronic diseases, advances in biologics, and newly approved pegylated pharmaceuticals are driving the worldwide pegylated market. Furthermore, high production costs, regulatory barriers, and potential adverse effects are limiting considerations for the market. However, expanding markets, novel medication delivery technologies, and customized medicine will give future market growth prospects.

The research includes a full overview of the pegylated antibody's benefits, market growth, driving forces, and challenges. It also sheds information on the leading key players' contributions and developments in the PEGylated Proteins Market.

The primary driving force behind the growth of the PEGylated Drugs Market is the rising prevalence of diseases such as cancer, the advancement of biologics sectors, and the expansion of pharmaceutical businesses worldwide. Furthermore, the rising incidence of chronic illnesses and cancer-related deaths in Canada will contribute to the expansion of pegylated pharmaceuticals in the market.

Market Segment Overview

The PEGylated Drugs Market is divided into three segments: molecule, indication, and region.

The Market is divided into three segments based on molecule: macromolecular drugs, small molecular drugs, and lipid nanoparticles (LNP) and liposomes.

The global pegylated pharmaceuticals market is divided into five applications: oncology, neurology, autoimmune diseases, haematology, and others.

The market is divided into three segments based on distribution channel: hospital pharmacies, retail pharmacies, and online pharmacies.

Regional analysis

The Global PEGylated Drugs Market has been classified by region: North America, Europe, Asia-Pacific, and the Rest of the World. North America held the greatest market share in 2024 and is expected to reach USD 8,969.41 million by 2035. However, Asia-Pacific is expected to develop at the fastest CAGR of 7.03% over the projection period.

The American market is separated into two regions: North and South America. The United States and Canada are the dominant regions in the North American market. The increased prevalence of chronic diseases, such as cancer, is driving market expansion.

The European government's assistance and investment in lowering chronic diseases is fueling the expansion of the regional market. The European continent is further divided into Western Europe and Eastern Europe. Western Europe is also divided into the United Kingdom, Italy, France, Spain, and the rest of Western Europe.

Major players.

Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Biogen, BioMarin Pharmaceutical Inc, Coherus BioSciences, Enzon, and Leadiant Biosciences, Inc. are among the companies operating in the PEGylated Drugs Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES
  • 4.2.2 ADVANCEMENTS IN BIOLOGICS
  • 4.2.3 RECENTLY APPROVED PEGYLATED DRUGS
• 4.3 RESTRAINTS
  • 4.3.1 HIGH PRODUCTION COSTS
  • 4.3.2 REGULATORY HURDLES
  • 4.3.3 POTENTIAL SIDE EFFECTS
• 4.4 OPPORTUNITY
  • 4.4.1 EMERGING MARKETS
  • 4.4.2 INNOVATIVE DRUG DELIVERY SYSTEMS
  • 4.4.3 PERSONALIZED MEDICINE

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 IMPACT OF COVID-19 ON THE GLOBAL PEGYLATED DRUGS MARKET
• 5.3 QUALITATIVE ANALYSIS ON ANTI-PEG ANTIBODIES AND IMPACT ON PEGYLATED DRUGS 50

6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE

• 6.1 OVERVIEW
• 6.2 MACROMOLECULAR DRUGS
  • 6.2.1 PROTEIN AND PEPTIDE
  • 6.2.2 ENZYME
  • 6.2.3 APTAMER
• 6.3 SMALL MOLECULAR DRUGS
• 6.4 LIPID NANOPARTICLES (LNP) AND LIPOSOMES

7 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 ONCOLOGY
• 7.3 NEUROLOGY
• 7.4 AUTOIMMUNE DISEASES
• 7.5 HAEMATOLOGY
• 7.6 OTHERS

8 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CAHNNEL

• 8.1 OVERVIEW
• 8.2 HOSPITAL PHARMACY
• 8.3 ONLINE PHARMACY
• 8.4 RETAIL PHARMACY

9 GLOBAL PEGYLATED DRUGS MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST & AFRICA
  • 9.5.2 SOUTH AMERICA
    • 9.5.2.1 BRAZIL
    • 9.5.2.2 MEXICO
    • 9.5.2.3 ARGENTINA
    • 9.5.2.4 REST OF SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 MARKET SHARE ANALYSIS, 2024
• 10.3 COMPETITOR DASHBOARD
• 10.4 PUBLIC PLAYERS STOCK SUMMARY
• 10.5 CMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT APPROVAL
  • 10.6.2 PRODUCT EXPANSION
  • 10.6.3 APPROVAL DENIED
  • 10.6.4 PRODUCT DISCONTINUATION
  • 10.6.5 AGREEMENT/ACQUISITION
  • 10.6.6 CLINICAL TRIAL FINDINGS

11 COMPANY PROFILES

• 11.1 AMGEN INC.
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 PFIZER INC.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 BIOGEN
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 KEY STRATEGIES
• 11.4 BAYER AG
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGY
• 11.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCT OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 KEY STRATEGIES
• 11.6 NOVO NORDISK A/S
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 SANDOZ GROUP AG
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 KEY STRATEGIES
• 11.8 ASTRAZENECA
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 KEY STRATEGIES
• 11.9 COHERUS BIOSCIENCES, INC.
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 F. HOFFMANN-LA ROCHE LTD.
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 SWOT ANALYSIS
  • 11.10.6 KEY STRATEGIES
• 11.11 JOHNSON & JOHNSON INC.
  • 11.11.1 COMPANY OVERVIEW
  • 11.11.2 FINANCIAL OVERVIEW
  • 11.11.3 PRODUCTS OFFERED
  • 11.11.4 KEY DEVELOPMENTS
  • 11.11.5 SWOT ANALYSIS
  • 11.11.6 KEY STRATEGIES
• 11.12 ALNYLAM PHARMACEUTICALS, INC.
  • 11.12.1 COMPANY OVERVIEW
  • 11.12.2 FINANCIAL OVERVIEW
  • 11.12.3 PRODUCTS OFFERED
  • 11.12.4 KEY DEVELOPMENTS
  • 11.12.5 KEY STRATEGIES
• 11.13 LES LABORATOIRES SERVIER
  • 11.13.1 COMPANY OVERVIEW
  • 11.13.2 FINANCIAL OVERVIEW
  • 11.13.3 PRODUCT OFFERED
  • 11.13.4 KEY DEVELOPMENTS
  • 11.13.5 KEY STRATEGIES

12 DATA CITATIONS